Login
Instil Bio, Inc. logo

Instil Bio, Inc.

instilbio.com

What Do They Do?

Seeks to in-license or acquire therapeutic candidates for development in diseases with significant unmet medical need.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $71.4M in FY2025.

Net income, FY2025
−556% of revenue
▲ +4% (Loss) vs FY2024 (−$74.1M, −659%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +69% (Loss)
vs −$13.6M in Q3 FY2025
  • Apr 1, 2026 Instil Bio replaced Deloitte with RSM as its independent auditor The audit committee appointed RSM for fiscal 2026 and dismissed Deloitte effective April 1, 2026.

Growing. Revenue grew 160.3x in 4 years, from $80K in FY2021 to $12.8M in FY2025, about 256% a year.

From cell therapy to candidate acquisition The older report describes a pipeline of engineered tumor-infiltrating lymphocyte therapies for cancer. The latest report instead focuses on seeking to in-license or acquire therapeutic candidates for development.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support